Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 77 of 103 for:    IVERMECTIN

Lymphatic Filariasis (LF) in Ivory Coast

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02974049
Recruitment Status : Completed
First Posted : November 28, 2016
Last Update Posted : April 26, 2019
Sponsor:
Collaborator:
Washington University School of Medicine
Information provided by (Responsible Party):
Christopher L. King, MD, PhD, Case Western Reserve University

Brief Summary:
The recommended treatment for elimination of LF in sub-Saharan Africa is annual mass drug administration (MDA) with single dose Albendazole (ALB) plus Ivermectin (IVM) given for at least 5-7 years. However, in areas where LF is co-endemic with a related filarial parasite, Loa loa, co-infection with L. loa represents a serious barrier to LF elimination because IVM used in LF MDA can result in severe reactions and even death in individuals with high microfilaria (mf) levels of L. loa. Screening for heavy L. loa infection is problematic. To overcome this problem, monotherapy with ALB is possible, since this drug has little or no effect on circulating mf and thus would not cause adverse effects in people with heavy L. loa infections. Moreover ALB has been shown to have embryostatic or embryocidal effects in female adult worms resulting in decreased mf levels with time as natural attrition of circulating mf occurs. Thus this open-label, randomized clinical trial will examine treatment with ALB monotherapy administered twice per year over a period of 3 years with the primary endpoint being the proportion of individuals with total clearance of mf at 36 months and Alere antigen test negativity (a more sensitive circulating antigen test of filarial infection). Two of the treatment arms will include ALB at two different doses, 400mg or 800mg (fixed dose twice yearly) as compared to standard treatment of ALB (400 mg) plus IVM (150-200 µg/kg) administered annually. Observations from an ongoing clinical trial in Papua New Guinea suggest that a single dose of triple therapy with ALB + IVM + DEC may be highly effective in sterilizing adult female worms. Therefore to confirm and expand these important preliminary observations in a different population, a fourth arm will be included in the current clinical trial in which subjects will receive all three drugs. The clinical trial will be performed in a region of Cote d'Ivoire where onchocerciasis and loiasis are not endemic.

Condition or disease Intervention/treatment Phase
Lymphatic Filariasis Drug: Albendazole Drug: Ivermectin Drug: Diethylcarbamazine Not Applicable

Detailed Description:

Lymphatic filariasis (LF) is a deforming and disabling infectious disease that causes elephantiasis and genital deformity (especially hydroceles). The infection affects some 120 million people in 81 countries in tropical and subtropical regions with well over 1 billion people at risk of acquiring the disease. LF is caused by Wuchereria bancrofti and Brugia spp. (B. malayi and B. timori), nematode parasites that are transmitted by mosquitoes. The World Health Organization (WHO) developed a plan for LF elimination that is based on using novel approaches to rapidly map endemic areas and 4 to 6 annual rounds of MDA with antifilarial medication. A recent summary from WHO reported that more than 4 billion doses of MDA were distributed between 2000 and 2012. Thus, the Global Program to Eliminate Lymphatic Filariasis (GPELF) is the largest infectious disease intervention program attempted to date based on MDA (Ottesen, Hooper et al.

2008). MDA has worked better in some areas than others. There are a number of challenges faced by GPELF. These include (among others) inability to conduct MDA programs in areas of Africa where L. loa is coendemic because of the unacceptable risk of Serious Adverse Events (SAE's) with IVM in persons with heavy L. loa infections (Hoerauf, Pfarr et al. 2011), the limited macrofilaricidal activity of current MDA regimens (especially ALB + IVM) that necessitate repeated annual rounds of MDA (Geary and Mackenzie , Hoerauf, Pfarr et al. 2011), and the difficulty of achieving high compliance rates for MDA over a period of years (Hoerauf, Pfarr et al. 2011). It is clear that new (or reformulated) drugs and/or dosing schedules for LF MDA have the potential to greatly improve the number of countries that will successfully eliminate LF by the WHO target date of 2020. This is especially important for areas of Central and West Africa where MDA has not been implemented because of the possible co-infection with L. loa and logistical and financial challenges to delivering annual doses of IVM + ALB MDA to millions of individuals over multiple years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 189 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire]
Actual Study Start Date : January 2015
Actual Primary Completion Date : September 2018
Actual Study Completion Date : September 25, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Standard Treatment
Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
Drug: Albendazole

Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole

Subjects in Arm 3 will receive 800mg of Albendazole

Other Name: ALB

Drug: Ivermectin
Subjects in Arms 1 and 4 will receive 200mg/kg body weight
Other Name: IVM

Experimental: ALB 400 mg x2 per year
Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
Drug: Albendazole

Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole

Subjects in Arm 3 will receive 800mg of Albendazole

Other Name: ALB

Experimental: ALB 800 mg x2 per year
Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
Drug: Albendazole

Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole

Subjects in Arm 3 will receive 800mg of Albendazole

Other Name: ALB

Experimental: ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg
Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only
Drug: Albendazole

Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole

Subjects in Arm 3 will receive 800mg of Albendazole

Other Name: ALB

Drug: Ivermectin
Subjects in Arms 1 and 4 will receive 200mg/kg body weight
Other Name: IVM

Drug: Diethylcarbamazine
Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
Other Name: DEC




Primary Outcome Measures :
  1. Total clearance of Microfilariae [ Time Frame: 36 months ]
    The percentage of participants with total clearance of Microfilariae


Secondary Outcome Measures :
  1. Total clearance of MF at 24 months [ Time Frame: 24 months ]
    Percentage of subjects with total clearance of MF at 24 months

  2. Percent MF reduction [ Time Frame: 24 and 36 months ]
    Percent MF reduction at 24 and 36 months compared to baseline level

  3. Reduction in W. bancrofti antigen level [ Time Frame: 12, 24 and 36 months ]
    Percent reduction in W. bancrofti antigen level measured by Og4C3 assay at 12, 24 and 36 months compared to baseline level

  4. Alere Filariasis Test Strip negative [ Time Frame: 12, 24 and 36 months ]
    Percentage of subjects that become Alere Filariasis Test Strip negative at 12, 24 and 36 months

  5. reduction in viable worm nests [ Time Frame: 12, 24, and 36 months ]
    Percent reduction in viable worm nests relative to baseline (time 0) based on follow up scrotal ultrasound examination performed at 12, 24 and 36 months

  6. Diversity of parasites [ Time Frame: 0 and 36 months ]
    Diversity of parasites before and after treatment using genetic markers

  7. type and level of parasite-specific host immune response [ Time Frame: 0 and 36 months ]
    Relation of type and level of parasite-specific host immune response with the initial and sustained clearance of parasites



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women and men 18-70 years
  • ≥50 MF/mL based on Nuclepore filtration
  • Willing to give informed consent

Exclusion Criteria:

  • Prior treatment for LF within last 5 years
  • Pregnancy (perform pregnancy test)
  • Hemoglobin <7 g/dL
  • Permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension
  • AST/ALT and creatinine >1.5 upper limit of normal
  • Proteinuria or hematuria >3+
  • Skin snip positivity for O. volvulus MF

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02974049


Sponsors and Collaborators
University Hospitals Cleveland Medical Center
Washington University School of Medicine
Investigators
Layout table for investigator information
Principal Investigator: Christopher L King, MD PhD Case Western Reserve University

Publications:
Chu, B. K., P. J. Hooper, M. H. Bradley, D. A. McFarland and E. A. Ottesen

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Christopher L. King, MD, PhD, Professor of International Health, Medicine and Pathology, Case Western Reserve University
ClinicalTrials.gov Identifier: NCT02974049     History of Changes
Other Study ID Numbers: 08-14-13
First Posted: November 28, 2016    Key Record Dates
Last Update Posted: April 26, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Not personal identifying data but infection levels will be shared.
Keywords provided by Christopher L. King, MD, PhD, Case Western Reserve University:
Ivermectin
Albendazole
Diethylcarbamazine
Additional relevant MeSH terms:
Layout table for MeSH terms
Ivermectin
Filariasis
Elephantiasis, Filarial
Elephantiasis
Spirurida Infections
Secernentea Infections
Nematode Infections
Helminthiasis
Parasitic Diseases
Lymphedema
Lymphatic Diseases
Albendazole
Diethylcarbamazine
Antiparasitic Agents
Anti-Infective Agents
Anthelmintics
Anticestodal Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Filaricides
Antinematodal Agents
Lipoxygenase Inhibitors
Enzyme Inhibitors